Morphic to Participate in RBC Capital Markets Global Healthcare Conference
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.
马萨诸塞州沃尔瑟姆，2024 年 5 月 9 日（GLOBE NEWSWIRE）— 形态疗法 纳斯达克股票代码：MORF）是一家开发用于治疗严重慢性病的新一代口服整合素疗法的生物技术公司，今天宣布，首席运营官兼首席财务官马克·谢格林博士将于5月15日星期三参加2024年加拿大皇家银行资本市场全球医疗保健会议的炉边谈话第四，美国东部时间上午 9:00。
A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.
加拿大皇家银行全球医疗大会小组讨论和炉边谈话的网络直播将在Morphic网站的投资者栏目上播出，网址为 www.morphictx.com。会议结束后，存档的重播将在公司的网站上公布。
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
关于形态疗法
Morphic Therapeal是一家生物制药公司，开发一系列口服整合素疗法，用于治疗严重的慢性病，包括自身免疫性疾病、心血管疾病和代谢性疾病、纤维化和癌症。Morphic还利用其专有的MinT技术平台，利用该公司对整合素结构和生物学的独特理解，与薛定哲合作推进其研发和发现活动。欲了解更多信息，请访问 www.morphictx.com。
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
联系人
形态疗法
克里斯·埃德曼
chris.erdman@morphictx.com
617.686.1718